High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open-label study. The goal of this clinical research
study is to investigate the efficacy and safety of adjuvant Toripalimab in high-risk
recurrent/secondary HNSCC after salvage surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University